BRPI0412282A - imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes - Google Patents

imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes

Info

Publication number
BRPI0412282A
BRPI0412282A BRPI0412282-8A BRPI0412282A BRPI0412282A BR PI0412282 A BRPI0412282 A BR PI0412282A BR PI0412282 A BRPI0412282 A BR PI0412282A BR PI0412282 A BRPI0412282 A BR PI0412282A
Authority
BR
Brazil
Prior art keywords
dsrna
specific
invertebrates
crustacean
methods
Prior art date
Application number
BRPI0412282-8A
Other languages
English (en)
Inventor
Paul Gross
Gregory Warr
Robert Chapman
Craig Browdy
Javier Robalino
Original Assignee
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev filed Critical Musc Found For Res Dev
Publication of BRPI0412282A publication Critical patent/BRPI0412282A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"IMUNIDADE ESPECìFICA E INESPECìFICA INDUZIDA POR dsRNA EM CRUSTáCEOS E OUTROS INVERTEBRADOS E VEìCULOS DE BIOLIBERAçãO PARA USO NESTES". São fornecidos métodos para a indução de respostas imunes sistêmicas, inespecíficas, e/ou com especificidade de seqüência em invertebrados, por exemplo, invertebrados marinhos, tais como moluscos, poríferos, ctenóforos, equinodermos, vermes marinhos, cnidários e, preferivelmente, crustáceos, pela administração de pelo menos um dsRNA, que confere imunidade contra um patógeno ou que modula a expressão gênica que afeta o crescimento, reprodução e saúde geral ou 'robustez'. Também são fornecidos métodos de identificação de genes de invertebrados, por exemplo, genes de crustáceos, cuja expressão esteja envolvida na indução de respostas imunes inespecíficas (sistêmicas) contra patógenos. Também são revelados sistemas de liberação e métodos preferidos para a administração de forma estável de pelo menos um dsRNA a um crustáceo, através do qual o dsRNA é administrado por meio de injeção, imersão, em uma ração ou meio nutriente ou contido em um microorganismo, por exemplo, levedura ou microalga, que expresse o referido dsRNA e seja passível de ingestão pelo referido crustáceo, por exemplo, um camarão.
BRPI0412282-8A 2003-07-02 2004-07-02 imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes BRPI0412282A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48453103P 2003-07-02 2003-07-02
US49860303P 2003-08-29 2003-08-29
US50571403P 2003-09-25 2003-09-25
US56429504P 2004-04-22 2004-04-22
PCT/US2004/021271 WO2005005613A2 (en) 2003-07-02 2004-07-02 Dsrna induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein

Publications (1)

Publication Number Publication Date
BRPI0412282A true BRPI0412282A (pt) 2006-09-19

Family

ID=34069336

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412282-8A BRPI0412282A (pt) 2003-07-02 2004-07-02 imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes

Country Status (4)

Country Link
US (1) US8633028B2 (pt)
JP (2) JP5183064B2 (pt)
BR (1) BRPI0412282A (pt)
WO (1) WO2005005613A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047495A2 (en) 2004-10-21 2006-05-04 Venganza Inc Methods and materials for conferring resistance to pests and pathogens of plants
CN100485036C (zh) * 2005-09-19 2009-05-06 中国科学院海洋研究所 一种中国明对虾抗菌蛋白基因及重组表达和应用
FR2908136A1 (fr) * 2006-11-07 2008-05-09 Ifremer Utilisation de peptides antimicrobiens comme marqueurs de resistance aux infections bacteriennes chez les crevettes peneides
US8097712B2 (en) * 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
FR2926367B1 (fr) * 2008-01-10 2013-01-04 Novaleads Procede fluorimetrique pour evaluer l'influence d'une condition sur un echantillon biologique et ses applications.
CN101981046B (zh) * 2008-02-04 2015-01-07 内盖夫研究与发展部本-古里安大学 对虾中的胰岛素样基因和其用途
US8440878B2 (en) 2008-02-04 2013-05-14 Ben-Gurion University Of The Negev Research And Development Authority Insulin-like gene in prawns and uses thereof
CN101617638B (zh) * 2008-07-04 2011-08-31 中国科学院海洋研究所 一种三疣梭子蟹抗病品系的构建方法
CA2760883A1 (en) 2009-05-05 2010-11-11 Beeologics Inc. Prevention and treatment of nosema disease in bees
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
EP2629599A4 (en) * 2010-10-22 2014-04-02 Donald Danforth Plant Sci Ct FIGHTING PATHOGENS AND PARASITES
EP2632486A1 (en) 2010-10-27 2013-09-04 Harrisvaccines Inc Method of rapidly producing vaccines for animals
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
CN102816815A (zh) * 2012-03-30 2012-12-12 浙江海洋学院 重组抗菌肽rCrustinI的酵母发酵生产方法
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
CN102787073B (zh) * 2012-07-13 2014-05-14 苏州大学 一种构建转基因家蚕微孢子虫的方法
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP3608412A3 (en) 2013-07-19 2020-04-08 Monsanto Technology LLC Compositions and methods for controlling leptinotarsa
KR102307389B1 (ko) 2013-10-04 2021-09-30 알닐람 파마슈티칼스 인코포레이티드 Ａｌａｓ1 유전자의 발현을 억제하기 위한 조성물 및 방법
WO2015153339A2 (en) 2014-04-01 2015-10-08 Monsanto Technology Llc Compositions and methods for controlling insect pests
UA125244C2 (uk) 2014-07-29 2022-02-09 Монсанто Текнолоджі Елелсі Спосіб умертвіння або припинення росту комахи
PL3256589T3 (pl) 2015-01-22 2022-02-21 Monsanto Technology Llc Kompozycje i sposoby kontrolowania leptinotarsa
WO2017009838A1 (en) 2015-07-14 2017-01-19 Transalgae Israel Ltd. Transgenic microalgae and use thereof as a feed for delivery of interfering rna molecules
US11091759B2 (en) 2015-12-07 2021-08-17 Genzyme Corporation Methods and compositions for treating a Serpinc1-associated disorder
US10844382B2 (en) 2016-04-11 2020-11-24 Microsynbiotix, Ltd. DNA constructs for manufacturing bio-therapuetic polypeptides for use in animal vaccines and therapeutics
CN109689106B (zh) * 2016-04-26 2023-01-24 微而广治疗有限公司 治疗虾类病毒感染的组合物和方法
TWI605816B (zh) * 2016-11-02 2017-11-21 國立屏東科技大學 針對酪氨酸羥化酶之雙股ｒｎａ的用途
PE20200483A1 (es) * 2017-03-31 2020-03-03 Pebble Labs Usa Inc Sistema novedoso para el biocontrol de patogenos en sistemas de acuicultura y otros sistemas animales
US11446339B2 (en) 2017-03-31 2022-09-20 Pebble Labs Inc. System for the biocontrol of white spot syndrome virus (WSSV) in aquaculture
CN106973864A (zh) * 2017-04-25 2017-07-25 遵义医学院 一种适用于白背飞虱注射法rna干扰实验的饲养装置及其使用方法
CN106942162A (zh) * 2017-04-25 2017-07-14 遵义医学院 一种适用于白背飞虱饲喂法rna干扰实验的装置及其使用方法
CN111433349A (zh) * 2017-08-07 2020-07-17 卵石实验室公司 用于急性肝胰腺坏死病的控制的系统和方法
CN109479899A (zh) * 2018-09-30 2019-03-19 中国农业科学院植物保护研究所 鞘翅目金龟类昆虫rna干扰的方法
CN109652420B (zh) * 2019-01-22 2022-06-14 汕头大学 一种高效抵抗WSSV的siRNA分子wsv147在制备抗WSSV制剂的应用
CN111304146B (zh) * 2020-03-11 2022-06-17 浙江省淡水水产研究所 一种促中华绒螯蟹造血组织发育免疫增强剂的筛选模型构建方法
CN113502337B (zh) * 2021-07-13 2022-03-22 华中农业大学 一种提高克氏原螯虾抗病能力的snp分子标记及应用
WO2023084510A1 (en) 2021-11-09 2023-05-19 Viaqua Therapeutics Ltd. Compositions for aquaculturing
WO2024033948A1 (en) * 2022-08-11 2024-02-15 Karyotica Biologicals Private Limited Chimeric dna targeted to white spot syndrome
CN115589972B (zh) * 2022-09-07 2023-10-20 南京市水产科学研究所 一种基于池塘改造的螺蛳河蟹接力生态养殖方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270175A (en) 1991-07-12 1993-12-14 Dna Plant Technology Corporation Methods and compositions for producing metabolic products for algae
GB9307408D0 (en) 1993-04-08 1993-06-02 Danisco Transgenic plants
JPH09201196A (ja) * 1996-01-25 1997-08-05 Koyu Kaku 白斑症候群関連バキュロウイルスの同定、精製および検出
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
SK287538B6 (sk) 1998-03-20 2011-01-04 Commonwealth Scientific And Industrial Research Organisation Syntetický gén obsahujúci dispergovanú alebo cudzorodú deoxyribonukleovú molekulu, génový konštrukt obsahujúci tento syntetický gén a prípravok obsahujúci tento syntetický gén
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR20000075076A (ko) 1999-05-28 2000-12-15 최태진 형질전환된 미세조류를 이용하여 외래 단백질을 생산하는 방법
ATE310089T1 (de) 1999-08-03 2005-12-15 Akzo Nobel Nv Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
SG144692A1 (en) * 2000-09-15 2008-08-28 Intervet Int Bv Antigenic proteins of shrimp white spot syndrome virus and uses thereof
US20020164706A1 (en) 2001-01-30 2002-11-07 Huang Lisa L. High level promoters from cyanobacteria
US6440466B1 (en) * 2001-02-21 2002-08-27 Council Of Scientific & Industrial Research Composition for treating white spot syndrome virus (WSSV) infected tiger shrimp penaeus monodon and a process for preparation thereof
AUPR621501A0 (en) * 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20040266708A1 (en) * 2002-01-29 2004-12-30 Paul Diamond Regulation of polynucleic acid activity and expression
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
EP1545600A4 (en) 2002-09-16 2006-07-12 Advanced Bionutrition Corp EXPRESSION OF PROTEINS AND PEPTIDES IN PASSIVE IMMUNITY
GB0306715D0 (en) 2003-03-24 2003-04-30 Novartis Ag Organic compounds
US20080194504A1 (en) 2004-02-06 2008-08-14 Advanced Bionutrition Corporation Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals
WO2007089732A2 (en) 2006-01-27 2007-08-09 Carnegie Institution Of Washington Improvement of levels and/or sustainability of dna-based gene expression
JP2008063302A (ja) * 2006-09-11 2008-03-21 Fisheries Research Agency クルマエビ属ホワイトスポット病用経口ワクチン
JP2008169131A (ja) * 2007-01-10 2008-07-24 Univ Of Miyazaki 甲殻類急性ウイルス血症に対するｄｎａワクチン
EP2188297B1 (en) * 2007-08-01 2012-02-01 Council of Scientific & Industrial Research Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent

Also Published As

Publication number Publication date
JP2007530414A (ja) 2007-11-01
WO2005005613A3 (en) 2005-06-02
US8633028B2 (en) 2014-01-21
JP5183064B2 (ja) 2013-04-17
WO2005005613A2 (en) 2005-01-20
US20050080032A1 (en) 2005-04-14
JP2012036187A (ja) 2012-02-23

Similar Documents

Publication Publication Date Title
BRPI0412282A (pt) imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes
Soonthornchai et al. Interaction of Vibrio spp. with the inner surface of the digestive tract of Penaeus monodon
Doetsch et al. Introduction to bacteria and their ecobiology
BR0103365A (pt) Sistema de acionamento
EP0876150A4 (en) NON-TOXIC MUTANTS OF GRAM-NEGATIVE PATHOGENIC BACTERIA
Liu et al. Infectious gastroenteritis caused by Vibrio harveyi (V. carchariae) in cultured red drum, Sciaenops ocellatus
Vosbeck et al. Effects of low concentrations of antibiotics on Escherichia coli adhesion
FI883763A0 (fi) Frigoering av vaerdens foersvarsmediatorer i biologiska vaetskor genom systematisk behandling med dubbelstraengat rna.
HK1078902A1 (en) Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
BRPI0411393A (pt) vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor
Kim et al. Growth promoting activity of Penaeus indicus by secondary metabolite producing probiotic bacterium Bacillus subtilis isolated from the shrimp gut
Priyaja et al. Pyocyanin (5-methyl-1-hydroxyphenazine) produced by Pseudomonas aeruginosa as antagonist to vibrios in aquaculture: Overexpression, downstream process and toxicity
Munang'andu et al. Vaccines and Immunostimulants for finfish
Wilkinson et al. [1] Chemotaxis: An overview
ATE338129T1 (de) Herstellung gegen sclerotinia sclerotiorum resistenter pflanzendurch einführung eines für oxalatoxydase kodierenden gens
Pooja et al. Endocytosis‒mediated invasion and pathogenicity of Streptococcus agalactiae in rat cardiomyocyte (H9C2)
NO20042248L (no) Anvendelse av enkeltcelleprotein som fôr for fisk og skalldyr
Austin Progress in understanding the fish pathogen Aeromonas salmonicida
Girardeau et al. Effect of glucose and amino acids on expression of K99 antigen in Escherichia coli
DE69110906D1 (de) Verwendung von Wirtszellphospholipiden zur Hemmung bakterieller Besiedlung.
Tu et al. Effect of temperature on survival and growth of infectious pancreatic necrosis virus
DE59611307D1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
Marathe et al. Influence of linoleic acid on quorum sensing in Proteus mirabilis and Serratia marcescens
MD3170G2 (ro) Procedeu de cultivare a infuzorilor Paramecium caudatum
Chung et al. Characterization of the probiotic properties of Lacticaseibacillus rhamnosus LR6 isolated from the vaginas of healthy Korean women against vaginal pathogens

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ARTIGO 10 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.